with us
together we’re making a difference

News Releases

Aug 12, 2026 |

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Aug 12, 2026 |

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Aug 10, 2026 |

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

Aug 06, 2026 |

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Jul 30, 2026 |

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

Jul 16, 2026 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Jul 14, 2026 |

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Jun 16, 2026 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 27, 2026 |

Annexon to Participate in Upcoming June Investor Conferences

May 18, 2026 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 21
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
investors@annexonbio.com

Media:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2026 Annexon Inc. All rights reserved.